Myology research highlights
RSS feedA natural history study of upper limb function in SMA type II
The Spanish network responsible for monitoring patients with SMN1-related proximal spinal muscular atrophy (SMA) retrospectively studied the evolution of upper limb function in SMA type II : 149 patients with type II SMA took part in the study, which consisted of measuring the Revised Upper Limb Module (RULM) functional score at regular intervals. The participants … [Read more]
Results of a European survey on the management of bone problems in neuromuscular diseases
The partial or total immobility caused by many neuromuscular diseases, whether or not associated with the deleterious effect of corticosteroid therapy, is often the cause of bone problems (osteoporosis, osteopenia, fractures, compression, etc.): The Euro-NMD neuromuscular reference network (ERN) has conducted a double survey on these complications, which are frequently encountered over the long term, … [Read more]
A revision of the classification of congenital myopathies in the light of recent discoveries
The team at the Créteil Neuromuscular Disease Reference Centre takes stock of congenital myopathies in the light of the recent exponential increase in knowledge in this field: in addition to the histological criteria which largely contributed to their original descriptions, genetics has enabled new entities to be discovered and their contours to be better defined, … [Read more]
Immune-mediated necrotising myopathy in children, a Chinese picture
A study conducted by a hospital in Beijing (China) has refined our knowledge of the phenotype of immune-mediated necrotising myopathy in paediatrics: 55 of the 116 children and adolescents followed up for myositis by this centre between 2012 and 2024 had immune-mediated necrotising myopathy, a much higher proportion (47.4%) than expected, but one that would … [Read more]
Positive results with gene therapy in a monkey model of DMD
A Chinese team has developed a rhesus monkey model of Duchenne muscular dystrophy, enabling it to evaluate a new gene therapy, with encouraging results. The DMDEx50 animal model has mutations in exon 50 of the DMD gene. A single-vector gene therapy called MyoAAV/Cas12iMax/sgRNA3Ex51 targeting exon 51 of the DMD gene was developed using Cas12iMax technology … [Read more]
Overexpressing utrophin in DMD: a new therapeutic approach in the spotlight
Chinese researchers have revived a therapeutic technique designed to over-express utrophin, an endogenous protein very similar to dystrophin: they used a genome-editing approach in several models (cellular and animal) of Duchenne muscular dystrophy (DMD) combined with a Myo-AAV muscle-specific viral vector (to obtain MyoAAV-UA). after administration, robust and long-lasting overexpression of utrophin was obtained in … [Read more]
Data from a cohort of 219 patients with distal myopathy provide further details on the characteristics of these diseases
Spanish doctors have published the demographic, clinical, genetic and physiological data from the largest cohort of patients with distal myopathy. With 219 patients included, the prevalence of distal myopathy in the Spanish population (in the Valencia region) is estimated at 3.9 per 100,000. The patients often presented with distal or proximodistal motor weakness that appeared … [Read more]
A significant advance in DMD cell therapy
British researchers have succeeded in significantly improving the grafting of myogenic progenitor cells (MPC) into the muscle fibre of mouse models of Duchenne muscular dystrophy: they used a special gel (hydrogel) to stabilise the donor cells so that they would take better hold in the muscle of the recipient mice, Stem cells from patients suffering … [Read more]
Towards a European register of autoimmune myasthenia gravis cases
At a time when innovative therapies are being developed for refractory forms of autoimmune myasthenia gravis, the idea of setting up a European register is gaining ground: to this end, a group of experts comprising 11 neurologists, 4 neuropaediatricians and a physiotherapist was brought together to define the most relevant items for the future register, … [Read more]
Valproic acid improves exon skipping efficiency in DMD mouse models
The major challenge of exon skipping therapy in Duchenne muscular dystrophy is to effectively deliver the antisense oligonucleotides to the targeted tissues, in this case the muscles. After obtaining encouraging results over four weeks, a French team assessed the benefits of combining valproic acid with antisense oligonucleotides designed to skip exon 23 of the DMD … [Read more]
